Disclosure obligations

In re Valsartan NDMA Products Liability Litig.

U.S. District Court, D.N.J. · US (NJ) · 2019 · Decided

Citation/Docket: 405 F. Supp. 3d 612 (D.N.J. 2019)

Parties & Funders

Posture: Defense motion for funding discovery
Funder(s) involved: (MDL plaintiffs' funders, if any)

Background

Defendants sought broad discovery of plaintiffs' litigation funding in the MDL.

Holding & Outcome

Denied, funding was irrelevant absent specific showing; NJ later adopted L. Civ. R. 7.1.1 (2021) requiring baseline funding disclosure statements.

Practical Lesson

Even disclosure-rule districts distinguish baseline identification from merits discovery into funding terms.

Related Disputes
In re National Prescription Opiate LitigationFulton v. Foley
Related Research Library Articles
The U.S. Disclosure PatchworkClass Actions and the Coming Disclosure FightProtecting Privilege When Sharing Materials With a Funder

Matters like this one often turn on expert testimony, on valuation, industry custom and practice, legal ethics, or damages. The Institute partners with world-class expert witness referral companies for this purpose.

Compiled from public sources (court filings, published opinions, and secondary reporting) as part of the Institute's Phase 1 Dispute Library research. This is educational material, not legal advice; case citations should be independently verified before relied upon.

← Back to the Dispute Library